Dr. Weiyong Sun, serving as the Chief Business Officer (CBO), currently leads Global Business Development and Alliance Management at Hansoh Pharmaceutical Group. Over the past five years, he and his team have accomplished over 20 licensing and collaboration deals, including two out-licensing agreements with GSK on ADCs in 2023, one small molecule GLP-1 out-licensing to Merck (MSD) in 2024, GLP-1/GIP dual peptide out-licensing to Regeneron and CDH17ADC out-licensing to Roche in 2025, and recently an emerging market out-licensing deal to Glenmark. Dr. Sun also plays a pivotal role in supporting Hansoh R&D by evaluating and accessing new technologies, platforms, and modalities.

 

Before joining Hansoh, Dr. Sun dedicated 19 years to Daiichi Sankyo, where he spent the initial five years in Tokyo R&D, contributing to activities ranging from target discovery to clinical development. Transitioning to the US Business Development division, he successfully identified, evaluated, and negotiated numerous partnership opportunities.

 

Dr. Sun holds an MD from Peking University Medical School, as well as master’s and doctoral degrees in Cell Biochemistry from the University of Tokyo. Additionally, he earned an MBA from Columbia Business School.